Fig. 6

Inhibition of SCD1 promotes the sensitivity of pancreatic cancer cells to the treatment of erastin and gemcitabine. A-D Ctrl and ZNF488 cells were seeded in 6-well plates. Then ZNF488 overexpressing cells were treated with erastin alone or combined with SCD1 inhibitors. A, B Colony formation was checked. C, D After treatment for 6 and 18 h, cell viability was measured by trypan blue staining. E, F ZNF488 overexpressing or knockdown pancreatic cancer cells were treated with different concentrations (0, 4 and 8µM) of gemcitabine for 48 h. Cell viability was assessed by trypan blue staining. G, H ZNF488 overexpressing pancreatic cancer cells were treated with gemcitabine alone (4µM) or combining with SCD1 inhibitors A939572 (50 nM) and erastin (3µM) for 24 and 48 h. Cell viability was detected by trypan blue staining. *p < 0.05. **p < 0.01